Schizencephaly is a malformation of cortical development characterized by gray matter-lined clefts in the cerebral cortex and a range of neurological presentations. In some cases, there are features of septo-optic dysplasia concurrently with schizencephaly. The etiologies of both schizencephaly and septo-optic dysplasia are thought to be heterogeneous, but there is evidence that at least some cases have genetic origin. We hypothesized that these disorders may be caused by mutations in three candidate genes: LHX2, a gene with an important cortical patterning role, and HESX1 and SOX2, genes that have been associated with septo-optic dysplasia. We sequenced a large cohort of patients with schizencephaly, some with features of schizencephaly, some with features of septo-optic dysplasia, and HESX1 and SOX2, genes that have been associated with septo-optic dysplasia. We sequenced a large cohort of patients with schizencephaly, some with features of septo-optic dysplasia, for mutations in these genes. No pathogenic mutations were observed, suggesting that other genes or non-genetic factors influencing genes critical to brain development must be responsible for schizencephaly.

Key words: schizencephaly; septo-optic dysplasia; LHX2; HESX1; SOX2

INTRODUCTION

Schizencephaly is an uncommon malformation of cortical development with an estimated prevalence in the United States of 1.54 per 100,000 individuals [Curry et al., 2005]. Patients with schizencephaly present with a broad range of neurological symptoms, including developmental delay, seizures, and hemiparesis or quadriplegia. Neuroimaging studies show unilateral or bilateral full thickness gray matter-lined clefts of the cerebral hemispheres. The two sides of a schizencephalic cleft can appear fused with a pial-ependymal seam (termed “closed lip”), or they can be separated by cerebrospinal fluid (“open lip”) [Yakovlev and Wadsworth, 1946a,b]. Such clefts are most often found in the perisylvian region, and the surrounding cortex is typically polymicrogyric [Barkovich and Norman, 1988; Barkovich and Kjos, 1992; Granata et al., 1996; Hayashi et al., 2002]. The suspected causes of schizencephaly are heterogeneous and remain poorly understood. Both genetic and non-genetic etiologies have been postulated [Bubis and Landau, 1964; Komarniski et al., 1990; Hehr et al., 2010]. There are few reported associations
with chromosomal aneuploidy, single gene defects, and distinct syndromes. Schizencephaly is usually simplex, but familial occurrence has been reported indicating one or more genetic factors for schizencephaly [Robinson 1991; Hosley et al., 1992; Hilburger et al., 1993; Tietjen et al., 2005].

A role for EMX2 was initially suggested in reports of multiplex and simplex cases [Capra et al., 1996; Failla et al., 1997; Granata et al., 1997], but more recent studies have not demonstrated a major role for EMX2 in schizencephaly [Tietjen et al., 2007; Merello et al., 2008; Hehr et al., 2010]. LH2X2, another gene expressed in the developing forebrain, specifies cortical fate in the hippocampus and neocortex [Hebert and Fishell, 2008] and has been hypothesized as a potential candidate gene for schizencephaly. Lhx2 knockout mice have a striking phenotype with an essentially absent neocortex [Monuki and Walsh, 2001; Mangale et al., 2008].

Schizencephaly is often associated with other CNS anomalies, including hydrocephalus, arachnoid cysts, and partial or complete absence of the septum pellucidum (ASP). In fact, up to 70% of cases of schizencephaly are associated with absent or abnormal septum pellucidum, and up to one-fourth of schizencephaly cases fall into the spectrum of septo-optic dysplasia (SOD) [Barkovich and Norman, 1988; Barkovich et al., 1989; Barkovich, 2005]. Conversely, nearly half of the patients reported with SOD have schizencephaly [Barkovich et al., 1989; Lau et al., 1993].

The coexistence of SOD and schizencephaly suggests potential common etiologies for both phenotypes. The majority of patients with SOD are simplex, and several etiologies have been postulated, including genetic abnormalities, viral infections, and vascular events. Some multiplex cases have been reported, supporting the role of genetics underlying SOD [Benner et al., 1990; Wales and Quarrell, 1996; Kelberman and Dattani, 2007]. Both homozygous and heterozygous missense mutations in HESX1 have been reported in association with SOD [Dattani et al., 1998; Thomas et al., 2001]. Mutations in HESX1 have also been reported in patients with ectopic posterior pituitary gland [Brickman et al., 2001] and in a patient with periventricular heterotopia and ectopic posterior pituitary gland [Mitchell et al., 2002]. The Hesx1 homeobox gene is expressed early in development in the mouse forebrain, and there is evidence for an important role for Hesx1/HESX1 in the development of mouse and human forebrain and pituitary gland [Dattani et al., 1998]. Given the evidence for a role of HESX1 in SOD and the frequent association between SOD and schizencephaly, we hypothesized that HESX1 mutations might be responsible for some proportion of simplex cases of schizencephaly.

The report of a patient with SOD and schizencephaly with a heterozygous mutation in SOX2 (c.389G > C, p.G130A) [Kelberman et al., 2006] makes this another attractive candidate gene for schizencephaly. SOX2, expressed in early neuroepithelial progenitors, is a transcription factor implicated in the development of the cerebral cortex, pituitary gland, eye, and inner ear.

Despite the strong suspicion of a genetic etiology for schizencephaly, the majority of cases remain unexplained. Based on the coexistence of schizencephaly and SOD, we hypothesized that mutations in genes previously shown to be mutated in patients with SOD can also cause schizencephaly, particularly in those patients with features of SOD but perhaps also in those without SOD. Given the associations described above, we evaluated 97 cases of schizencephaly, including 13 with both schizencephaly and features of SOD, to screen for mutations in LHX2, HESX1, and SOX2.

**SUBJECTS AND METHODS**

**Subjects**

This study was conducted with the approval of the Institutional Review Board of Children’s Hospital Boston and the Beth Israel Deaconess Medical Center. Subjects with schizencephaly were identified from a large research database of brain malformation cases (Walsh Laboratory) and from the California Birth Defects Monitoring Program (CBDMP). In the cases ascertained from the Walsh Laboratory research database, informed consent was obtained from the patients or their parents/guardians. Data and DNA from the CBDMP were de-identified and made available for inclusion in this study. We reviewed the medical records and MRIs (magnetic resonance imaging) of all potential cases when these data were available. We classified schizencephaly with regard to open versus closed lip and to laterality. In patients with schizencephaly and features consistent with SOD, we performed a more detailed analysis of the MRIs, including SOD-related features, and associated clinical features.

**Genetic Analysis**

Blood was collected by venipuncture from patients diagnosed with schizencephaly. Genomic DNA was extracted from peripheral blood lymphocytes using standard techniques. Primers were designed for sequencing of LHX2, HESX1, and SOX2; we sequenced all exons and exon–intron junctions in the forward and reverse directions (Polyomorphmic DNA Technologies, Alameda, CA). Sequencing data were analyzed using Variant Report and DNAStar software. When polymorphisms were observed, we interpreted them using the UCSC Genome Browser 2006 Assembly (http://www.genome.ucsc.edu). Based on our initial observations, we designed forward and reverse primers for exon 3 of LHX2 using Primer 3 software, and we screened 574 control chromosomes from a panel of 287 Caucasian control samples.

**RESULTS**

**Clinical Description of Schizencephaly Patients**

We analyzed the available clinical and MRI data from 97 patients identified from the Walsh Laboratory research database (n = 39) and the CBDMP (n = 58). We confirmed the diagnosis of schizencephaly when possible by review of MRI data and/or medical records. Representative patients of open and closed lip schizencephaly are shown in Figure 1.

For the CBDMP patients, while only information about the schizencephaly type was available to us, this population has been well described in the past [Curry et al., 2005].

**Schizencephaly type.** Of the 97 patients included in our analysis, there was sufficient information about the laterality and lip type
to be able to classify the schizencephaly in 75. Fourteen had unilateral open lip schizencephaly, 13 unilateral closed lip, 20 bilateral open lip, and four bilateral closed lip, as shown in Table I. Five patients had a combination of open and closed lip schizencephaly, one unilateral (two clefts in the same hemisphere) and four bilateral. Nineteen patients had unknown lip type, but information about laterality was available (12 unilateral and seven bilateral).

**Patients with Schizencephaly and SOD.** We observed 14 patients in which there was schizencephaly with coexistent SOD on the basis of neuroimaging features, such as ASP, optic nerve hypoplasia, and pituitary gland abnormalities, detailed in Table II. In this subset of patients, eight were male and six female; the age at ascertainment ranged from 22 days to 37 years.

The MRI results for this group demonstrated a range of SOD-related abnormalities. Nine patients had a single SOD-related feature: five had an abnormality of the septum pellucidum (Patients 6, 7, 8, 10, and 14), three had pituitary abnormalities (Patients 1, 3, and 4), and one had bilateral optic nerve hypoplasia (Patient 5). Notably, Patient 3 also had visual impairment, suggesting involvement of the optic pathway, though this was not evident on imaging. Four patients had two SOD-related imaging findings: Patient 2 had thin optic nerves and hypoplastic pituitary, and three patients had ASP plus hypoplasia of the optic nerves or pathway (Cases 9, 11, and 12). Patient 13, had three SOD-related imaging features: ASP, bilateral optic nerve and chiasm hypoplasia, and absent posterior pituitary.

All but patients with schizencephaly and SOD had additional MRI abnormalities, including ventriculomegaly, agenesis or abnormality of the corpus callosum, diminished white matter volume and/or delayed myelination, and polymicrogyria. Some other features occurred in only single patients and are listed in Table II. The clinical features of this group included features classically attributed to schizencephaly (developmental delay, seizures, hemiparesis, and quadriplegia). There was a paucity of SOD-related clinical features reported: only one patient had pituitary dysfunction (Patient 2), and only one had visual impairment (Patient 3).

**Interpretation of candidate gene sequencing**

Analysis of sequencing of the *LHX2*, *HESX1*, and *SOX2* exons and exon–intron junctions in 97 cases of schizencephaly did not reveal mutations that were likely to be pathogenic. We observed several polymorphisms, some published and some not previously reported (Table III).

**LHX2.** In a single case of schizencephaly, we observed a heterozygous c.724G > A change, resulting in p.Ala242Thr. Though this is a conserved alanine residue, it is located only 3 bp from a large insertion/deletion polymorphism (rs71801713 at chr9:125,817,625–125,823,197) and does not fall in the region of any of the well characterized functional LHX2 protein domains [http://www.uniprot.org]. We screened 287 Caucasian controls (574 chromosomes) and did not find the c.724G > A change, suggesting that it is not a common polymorphism.

We observed three previously reported SNPs: rs7868184 in exon 1 (n = 4, three heterozygous, one homozygous), rs61734362 in exon 4 (n = 1, heterozygous), and rs1042486 in exon 4 (n = 46, 35 heterozygous, 11 homozygous). The high frequency of rs1042486 in our group of cases is consistent with the reported rates of 42–52% in Caucasian and Asian samples (HapMap-CEU and HapMap-CHB and JPT; http://hapmap.ncbi.nlm.nih.gov). Five patients had a G > T heterozygous change in intron 3; the native G is not highly conserved across species, but the polymorphism occurs in non-coding sequence. One patient had a synonymous change in exon 5, c.1017C > G.

**HESX1.** In three patients with schizencephaly, including one with SOD features (Patient 3) we observed an apparent heterozygous missense mutation in *HESX1*, c.374A > G (p.As125Ser). However, since this polymorphism has been
| Case | Sex | Age          | Schizencephaly type | Features consistent with SOD                      | Other brain imaging findings                                      | Clinical features                        |
|------|-----|--------------|---------------------|--------------------------------------------------|-------------------------------------------------------------------|------------------------------------------|
| 1    | M   | 22 day       | Left closed lip     | Ectopic posterior pituitary lobe                  | Possible focal cortical dysplasia, left temporal lobe              | Macrocephaly                            |
| 2    | M   | 1 month      | Bilateral Open lip on right | Thin optic nerves (autopsy) Hypoplastic pituitary | Immature gyral pattern, Absent splenium of corpus callosum, Ventriculomegaly | Panhypopituitarism, Seizures             |
| 3    | F   | 2 years, 5 months | Bilateral Four open lip clefts | Hypoplastic pituitary, absent posterior pituitary | Agenesis of the corpus callosum Reduced white matter volume Delayed myelination | Hypoplastic brain stem, Generalized polymicrogyria, Developmental delay, Visually impairment, Hypertelorism, Ventriculo-peritoneal shunt |
| 4    | M   | 8 months     | Right open lip      | Hypoplastic pituitary                            | Ventriculomegaly                                                  | Died, 1-month-old, Microcephaly          |
| 5    | M   | 2 years      | Bilateral closed lip | Bilateral optic nerve hypoplasia                 | None                                                              | Developmental delay                      |
| 6    | F   | 27 years     | Right open lip      | Absent septum pellucidum                        | Left hemisphere polymicrogyria Thin posterior body of corpus callosum Reduced white matter volume Right-sided ventriculomegaly | Developmental delay, Left spastic hemiparesis, Choreoathetosis in the left hand, Dysarthric speech |
| 7    | M   | 20 years     | Right open lip      | Absent septum pellucidum                        | Left hemisphere cortical dysplasia Thin posterior body of corpus callosum Reduced white matter volume Right-sided ventriculomegaly | Developmental delay, Left spastic hemiparesis, Choreoathetosis in the left hand, Dysarthric speech |
| 8    | M   | 21 years     | Right closed lip    | Absent septum pellucidum                        | Left hemisphere cortical dysplasia Thin posterior body of corpus callosum Reduced white matter volume Right-sided ventriculomegaly | Developmental delay, Left spastic hemiparesis, Choreoathetosis in the left hand, Dysarthric speech |
| 9    | M   | 2 years      | Bilateral open lip  | Absent septum pellucidum Bilateral optic nerve hypoplasia | Ventricular heterotopia contiguous with clefts Dysmorphic [thick, foreshortened] corpus callosum Reduced white matter volume Reduced white matter volume | Developmental delay, Spastic quadriparesis |
| 10   | F   | 3 years      | Right closed lip    | Absent septum pellucidum                        | Reduced white matter volume                                        | Developmental delay, Left hemiparesis    |
| 11   | F   | 2 years      | Right open lip      | Absent septum pellucidum Bilateral optic nerve hypoplasia and hypoplasia of optic chiasm | Polymicrogyria Reduced white matter volume Calciums in ventricular walls, Small right cerebral peduncle, pons, and medullary pyramid | Developmental delay, Left hemiparesis    |
observed to occur in 35% of a large, Sub-Saharan African control sample (HapMap-YRI) (http://hapmap.ncbi.nlm.nih.gov) and has been published in dbSNP as rs9878928, we concluded that it was not pathogenic.

**SOX2.** We observed one heterozygous change in *SOX2*: c.*22G > A (exon 1 + 22 bp) in two patients, including one with SOD features (Case 12). Though not yet published in dbSNP, this polymorphism, occurring in a non-coding nucleotide that is not highly conserved, has been reported in unaffected controls [Fantes et al., 2003; Bakrania et al., 2007].

**DISCUSSION**

Though schizencephaly is a heterogeneous condition, we strongly suspect that some cases have an underlying genetic etiology. Nonetheless, there are to date no genes identified that play a major role in this condition. We hypothesized that mutations in *LHX2* might give rise to schizencephaly given the important role of *LHX2* in cortical patterning. Because of the overlap sometimes observed between schizencephaly and SOD, we also hypothesized that genes associated with SOD—*HESX1* and *SOX2*—might also cause some cases of schizencephaly.

We observed several polymorphisms in *LHX2*, including published SNPs. One *LHX2* sequence variation, c.724G > A, had not been previously reported. Though it is synonymous, this does not occur in any of the functionally important *LHX2* domains and is adjacent to a large known polymorphism. Thus, we concluded that this change represents a benign though uncommon polymorphism. We observed only one polymorphism in *HESX1*; even though it represented a non-synonymous variation in the amino acid sequence, it is a previously reported common polymorphism (http://hapmap.ncbi.nlm.nih.gov). Similarly, we observed a polymorphism in the 3′-UTR of *SOX2* in a single case that we concluded was not pathogenic [Fantes et al., 2003; Bakrania et al., 2007].

From a total of 97 cases of schizencephaly, there were 14 with concurrent features suggestive of SOD, including ASP, optic nerve hypoplasia, and pituitary gland abnormalities. As this is a retrospective study and full records were not available from all cases, it is difficult to estimate accurately the true coincidence of SOD among all studied cases of schizencephaly. Our findings in a large but heterogeneous group of subjects with schizencephaly, a subset of whom had features of SOD, indicate that these candidate genes do not account for a significant fraction of schizencephaly or schizencephaly + SOD cases.

It is clear from familial studies that at least some occurrences of schizencephaly have a genetic etiology, but the extent to which genetic causes can explain these conditions remains unknown. The observation of schizencephaly in combination with some or all of the features of SOD in some patients may be secondary to concomitant injury to multiple structures in the developing brain. It is plausible that some mutations may cause schizencephaly by increasing the susceptibility of the developing brain to environmental events. Additional studies will be needed to better define the genetic and non-genetic factors that contribute to schizencephaly.
TABLE III. Sequence Changes in *LHX2*, *HESX1*, and *SOX2* in Schizencephaly Cases

| Gene | Exon | Chromosome position | SNP Id (dbSNP129) | Variant | Frequency (%) | Interpretation |
|------|------|---------------------|-------------------|---------|---------------|----------------|
| *LHX2* | Exon 1 | Chr9: 125,814,336 | rs1986814 | c.113G > T | 4/9? (4) | 5’-UTR |
| *LHX2* | Exon 3 | Chr9: 125,817,622 | n/a | c.724G > A | 1/9? (1) | p.A242T, conserved* |
| *LHX2* | Intron 3 | Chr9: 125,823,178 | n/a | c.728–216 > T | 5/9? (5) | Intron, not conserved |
| *LHX2* | Exon 4 | Chr9: 125,823,236 | rs61734362 | c.765C > T | 1/9? (1) | p.D255D |
| *LHX2* | Exon 4 | Chr9: 125,823,254 | rs1042486 | c.783G > C | 46/9? (45) | p.P261P |
| *LHX2* | Exon 5 | Chr9: 125,834,603 | n/a | c.1017C > G | 1/9? (1) | p.A339A |
| *HESX1* | Exon 3 | Chr3: 57,207,544 | rs9878928 | c.374A > G | 3/9? (3) | N125S |
| *SOX2* | Exon 1 | Chr3: 182,913,818 | n/a | c.22G > A | 2/9? (2) | 3’-UTR, not conserved |

n/a, not applicable.

*3 bp from rs71801713, a large insertion/deletion polymorphism.

ACKNOWLEDGMENTS

We thank the patients and families who participated in this research. A.P. was supported by a Child Health Research Center Scholar K12 award to the Department of Medicine, Children’s Hospital Boston (grant 5K12HD052896-04). B.S.C. (grant K23 NS049159), A.J.B. and C.A.W. (grant R37NS35129) were supported by the NIH/NINDS. C.A.W. is an Investigator of the Howard Hughes Medical Institute.

We thank the California Department of Public Health Maternal Child and Adolescent Health Division for providing data for these analyses. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the California Department of Public Health.

REFERENCES

Bakrania P, Robinson DO, Bunyan DJ, Salt A, Martin A, Crolla JA, Wyatt A, Fielder A, Ainsworth J, Moore A, Read S, Uddin J, Laws D, Pascuel-Salcedo D, Ayuso C, Allen L, Collin JR, Ragg NK. 2007. SOX2 anophthalmia syndrome: 12 New cases demonstrating broader phenotype and high frequency of large gene deletions. Br J Ophthalmol 91:1471–1476.

Barkovich AJ, Fram EK, Norman D. 2005. Pediatric neuroimaging, Fourth edition. Philadelphia, PA: Lippincott Williams & Wilkins. p 334–337.

Benner JD, Preslan MW, Gratz E, Joslyn J, Schwartz M, Kelman S. 1990. Septo-optic dysplasia in two siblings. Am J Ophthalmol 109:632–637.

Brickman JM, Clements M, Tyrell R, McNay D, Woods K, Warner J, Stewart A, Beddington RS, Dattani M. 2001. Molecular effects of novel mutations in Hex1/HESX1 associated with human pituitary disorders. Development 128:5189–5199.

Bubis JJ, Landau WM. 1964. Agenesis of pyramidal tracts associated with schizencephalic clefts in rolandic cortex. Neurology 14:821–824.

Capra V, De Marco P, Moroni A, Faiella A, Brunelli S, Tortori-Donati P, Andreussi I, Boncinelli E, Cama A. 1996. Schizencephaly: Surgical features and new molecular genetic results. Eur J Pediatr Surg 6:27–29.

Curry CJ, Lammer EJ, Nelson V, Shaw GM. 2005. Schizencephaly: Heterogeneous etiologies in a population of 4 million California births. Am J Med Genet Part A 137A:181–189.

Dattani MT, Martinez-Barbera JP, Thomas PQ, Brickman JM, Gupta R, Martensson IL, Toresson H, Fox M, Wales JK, Hindmarsh PC, Krauss S, Beddington RS, Robinson IC. 1998. Mutations in the homeobox gene HESX1/Hesx1 associated with septo-optic dysplasia in human and mouse. Nat Genet 19:125–133.

Fantes J, Ragge NK, Lynch SA, McGill NI, Collin JR, Howard-Peebles PN, Hayward C, Vivian AJ, Williamson K, van Heyningen V, FitzPatrick DR. 2003. Mutations in SOX2 cause anophthalmia. Nat Genet 33:461–463.

Granata T, Battaglia G, D’Incerti L, Cardini R, Lenti C, Battaglia G, Boncinelli E. 1997. A number of schizencephaly patients including 2 brothers are heterozygous for germline mutations in the homeobox gene EMX2. Eur J Hum Genet 5:186–190.

Hayashi N, Tsutsuji Y, Barkovich AJ. 2002. Morphological features and associated anomalies of schizencephaly in the clinical population: Detailed analysis of MR images. Neuroradiology 44:418–427.

Hebert JM, Fishell G. 2008. The genetics of early telencephalon patterning: Some assembly required. Nat Rev Neurosci 9:678–685.

Hosley MA, Abrons IF, Ragland RL. 1992. Schizencephaly: Case report of familial incidence. Pediatr Neurol 8:148–150.

Kelberman D, Rizzoti K, Avilion A, Bitner-Glindzicz M, Cianfarani S, Collins J, Chong WK, Kirk JM, Achermann JC, Ross R, Carmignac D, Lovell-Badge R, Robinson IC, Dattani MT. 2006. Mutations within...
Sox2/SOX2 are associated with abnormalities in the hypothalamo-pituitary-gonadal axis in mice and humans. J Clin Invest 116:2442–2455.

Kelberman D, Dattani MT. 2007. Genetics of septo-optic dysplasia. Pituitary 10:393–407.

Komarniski CA, Cyr DR, Mack LA, Weinberger E. 1990. Prenatal diagnosis of schizencephaly. J Ultrasound Med 9:304–307.

Lau KY, Tam W, Lam PK, Wood BP. 1993. Radiological cases of the month. Septo-optic dysplasia (De Morsier syndrome). Am J Dis Child 147:71–72.

Mangale VS, Hirokawa KE, Satyaki PR, Gokulchandran N, Chikbire S, Subramanian I, Shetty AS, Martynoga B, Paul J, Mai MV, Li Y, Flanagan LA, Tole S, Monuki ES. 2008. Lhx2 selector activity specifies cortical identity and suppresses hippocampal organizer fate. Science 319:304–309.

Merello E, Swanson E, De Marco P, Akhter M, Striano P, Rossi A, Cama A, Leventer RJ, Guerrini R, Capra V, Dobyns WB. 2008. No major role for the EMX2 gene in schizencephaly. Am J Med Genet Part A 146A:1142–1150.

Mitchell LA, Thomas PQ, Zacharin MR, Scheffer IE. 2002. Ectopic posterior pituitary lobe and periventricular heterotopia: Cerebral malformations with the same underlying mechanism? Am J Neuroradiol 23:1475–1481.

Monuki ES, Walsh CA. 2001. Mechanisms of cerebral cortical patterning in mice and humans. Nat Neurosci 4(Suppl):1199–1206.

Robinson RO. 1991. Familial schizencephaly. Dev Med Child Neurol 33:1010–1012.

Thomas PQ, Dattani MT, Brickman JM, McNay D, Warne G, Zacharin M, Cameron F, Hurst J, Woods K, Dunger D, Stanhope R, Forrest S, Robinson IC, Beddington RS. 2001. Heterozygous HESX1 mutations associated with isolated congenital pituitary hypoplasia and septo-optic dysplasia. Hum Mol Genet 10:39–45.

Tietjen I, Erdogan F, Currier S, Apse K, Chang BS, Hill RS, Lee CK, Walsh CA. 2005. EMX2-independent familial schizencephaly: Clinical and genetic analyses. Am J Med Genet Part A 135A:166–170.

Tietjen I, Bodell A, Apse K, Mendonza AM, Chang BS, Shaw GM, Barkovich AJ, Lammer EJ, Walsh CA. 2007. Comprehensive EMX2 genotyping of a large schizencephaly case series. Am J Med Genet Part A 143A:1313–1316.

Wales JK, Quarrell OW. 1996. Evidence for possible Mendelian inheritance of septo-optic dysplasia. Acta Paediatr 85:391–392.

Yakovlev PI, Wadsworth RC. 1946a. Schizencephalies: A study of the congenital clefts in the cerebral mantle, II: Clefts with hydrocephalus and lips separated. J Neuropathol Exp Neurol 5:169–206.

Yakovlev PI, Wadsworth RC. 1946b. Schizencephalies: A study of the congenital clefts in the cerebral mantle, I: Clefts with fused lips. J Neuropathol Exp Neurol 5:116–130.